177 related articles for article (PubMed ID: 11950550)
21. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.
Brunette MF; Drake RE; Xie H; McHugo GJ; Green AI
Schizophr Bull; 2006 Oct; 32(4):637-43. PubMed ID: 16782758
[TBL] [Abstract][Full Text] [Related]
22. Patterns of current and lifetime substance use in schizophrenia.
Fowler IL; Carr VJ; Carter NT; Lewin TJ
Schizophr Bull; 1998; 24(3):443-55. PubMed ID: 9718636
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of cough mixture abusers referred to three substance abuse clinics in Hong Kong: a retrospective study.
Tang AK; Tang WK; Liang HJ; Chan F; Mak SC; Ungvari GS
East Asian Arch Psychiatry; 2012 Dec; 22(4):154-9. PubMed ID: 23271584
[TBL] [Abstract][Full Text] [Related]
24. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.
Piette JD; Heisler M; Ganoczy D; McCarthy JF; Valenstein M
Psychiatr Serv; 2007 Feb; 58(2):207-12. PubMed ID: 17287377
[TBL] [Abstract][Full Text] [Related]
25. The effects of cognitive impairment and substance abuse on psychiatric hospitalizations.
Jackson CT; Fein D; Essock SM; Mueser KT
Community Ment Health J; 2001 Aug; 37(4):303-12. PubMed ID: 11482748
[TBL] [Abstract][Full Text] [Related]
26. Drug abuse in schizophrenia: comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission.
Silver H; Abboud E
Schizophr Res; 1994 Aug; 13(1):57-63. PubMed ID: 7947416
[TBL] [Abstract][Full Text] [Related]
27. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
Diaz E; Levine HB; Sullivan MC; Sernyak MJ; Hawkins KA; Cramer JA; Woods SW
J Psychiatry Neurosci; 2001 Sep; 26(4):325-9. PubMed ID: 11590972
[TBL] [Abstract][Full Text] [Related]
28. Substance abuse and clozapine treatment.
Buckley P; Thompson PA; Way L; Meltzer HY
J Clin Psychiatry; 1994 Sep; 55 Suppl B():114-6. PubMed ID: 7961553
[TBL] [Abstract][Full Text] [Related]
29. The effects of clozapine on aggression and substance abuse in schizophrenic patients.
Volavka J
J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611
[TBL] [Abstract][Full Text] [Related]
30. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
[TBL] [Abstract][Full Text] [Related]
31. Retrospective study of 2,200 involuntary psychiatric admissions and readmissions.
Sanguineti VR; Samuel SE; Schwartz SL; Robeson MR
Am J Psychiatry; 1996 Mar; 153(3):392-6. PubMed ID: 8610828
[TBL] [Abstract][Full Text] [Related]
32. Continuing care after inpatient psychiatric treatment for patients with psychiatric and substance use disorders.
Ilgen MA; Hu KU; Moos RH; McKellar J
Psychiatr Serv; 2008 Sep; 59(9):982-8. PubMed ID: 18757590
[TBL] [Abstract][Full Text] [Related]
33. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.
Buckley P; Thompson P; Way L; Meltzer HY
Am J Psychiatry; 1994 Mar; 151(3):385-9. PubMed ID: 8109646
[TBL] [Abstract][Full Text] [Related]
34. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders.
Drake RE; McHugo GJ; Xie H; Fox M; Packard J; Helmstetter B
Schizophr Bull; 2006 Jul; 32(3):464-73. PubMed ID: 16525088
[TBL] [Abstract][Full Text] [Related]
35. Predicting medication noncompliance after hospital discharge among patients with schizophrenia.
Olfson M; Mechanic D; Hansell S; Boyer CA; Walkup J; Weiden PJ
Psychiatr Serv; 2000 Feb; 51(2):216-22. PubMed ID: 10655006
[TBL] [Abstract][Full Text] [Related]
36. Substance abuse among adolescents with chronic mental illnesses: a pilot study of descriptive and differentiating features.
Kutcher S; Kachur E; Marton P; Szalai J; Jaunkalns R
Can J Psychiatry; 1992 Aug; 37(6):428-31. PubMed ID: 1394021
[TBL] [Abstract][Full Text] [Related]
37. [Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders].
Verdoux H; Mury M; Besançon G; Bourgeois M
Encephale; 1996; 22(2):95-101. PubMed ID: 8706627
[TBL] [Abstract][Full Text] [Related]
38. Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission.
Vaughan K; McConaghy N; Wolf C; Myhr C; Black T
Aust N Z J Psychiatry; 2000 Oct; 34(5):801-8. PubMed ID: 11037366
[TBL] [Abstract][Full Text] [Related]
39. The cost of relapse in schizophrenia and schizoaffective disorder.
Fitzgerald P; de Castella A; Arya D; Simons WR; Eggleston A; Meere S; Kulkarni J
Australas Psychiatry; 2009 Aug; 17(4):265-72. PubMed ID: 19585288
[TBL] [Abstract][Full Text] [Related]
40. Prediction of compliance with outpatient referral in patients with schizophrenia and psychoactive substance use disorders.
Miner CR; Rosenthal RN; Hellerstein DJ; Muenz LR
Arch Gen Psychiatry; 1997 Aug; 54(8):706-12. PubMed ID: 9283505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
